ABSTRACT: Cyclin-dependent kinases (CDKs) are serine/ threonine protein kinases that act as key regulatory elements in cell cycle progression. We describe the development of highly potent diaminothiazole inhibitors of CDK2 (IC 50 = 0.0009−0.0015 μM) from a single hit compound with weak inhibitory activity (IC 50 = 15 μM), discovered by high-throughput screening. Structure-based design was performed using 35 cocrystal structures of CDK2 liganded with distinct analogues of the parent compound. The profiling of compound 51 against a panel of 339 kinases revealed high selectivity for CDKs, with preference for CDK2 and CDK5 over CDK9, CDK1, CDK4, and CDK6. Compound 51 inhibited the proliferation of 13 out of 15 cancer cell lines with IC 50 values between 0.27 and 6.9 μM, which correlated with the complete suppression of retinoblastoma phosphorylation and the onset of apoptosis. Combined, the results demonstrate the potential of this new inhibitors series for further development into CDK-specific chemical probes or therapeutics.
■ INTRODUCTION
Protein kinases have been implicated in a myriad of human diseases, including various cancers and neurodegenerative disorders. Cyclin-dependent kinases (CDKs) are a family of serine/threonine kinases that are involved in cell cycle progression and transcription. Deregulation of CDKs has been associated with a number of medical conditions, and they have therefore become validated and important targets in drug discovery. 1, 2 The functionality of CDKs is dependent on specific interactions with regulatory partner proteins, the cyclins. 3−5 Cell-cycle progression depends on the activity of CDK1, CDK2, CDK4, and CDK6. CDK4/6 in complex with cyclin D1, D2, or D3 and CDK2 in complex with cyclin E promote S-phase entry by phosphorylating and inactivating the retinoblastoma (Rb) protein. CDK2-cyclin A and CDK1-cyclin A propel cells through the S-phase, and CDK1-cyclin B is responsible for mitosis. 6 ,7 CDK-specific inhibitors induce apoptosis by repressing transcription and/or by perturbing the cell cycle. 8 As alterations in checkpoint regulation can lead to aberrant cell division, CDK2 represents an attractive target for therapeutics designed to arrest or recover control of the cell cycle. 9, 10 Additionally, CDK2 is essential for completion of prophase I during meiotic cell division in male and female germ cells, and CDK2−/− knockout mice are viable but sterile. 11−13 Therefore, CDK2 also provides promise as a target for the development of nonhormonal male contraceptive agents that do not exhibit the significant side effects associated with hormone-based agents currently available for female contraception and under development for male contraception. Several CDK inhibitors have been in clinical development since the 1990s. These first-generation inhibitors, namely flavopiridol, (R)-roscovitine, SNS-032, 17 and PHA-793887, 18 were discontinued during phase II or phase III trials due to unfavorable pharmacological properties and low specificity resulting in undesirable off-target interactions. Recently, two new-generation CDK inhibitors, dinaciclib (Merck, SCH727965) and palbociclib (Pfizer, PD-0332991), advanced to phase III trials for refractory chronic lymphocytic leukemia and advanced estrogen receptor (ER)-positive breast cancer, respectively. 19, 20 Dinaciclib is a selective inhibitor of CDK1, CDK2, CDK5, and CDK9, 21, 22 while palbociclib is a selective inhibitor of CDK4 and CDK6. 23 In an attempt to discover new CDK2 inhibitors with promising scaffolds for hit-to-lead development, we screened 103000 compounds from commercial libraries against the human CDK2-cyclin A2 complex. Hit compound 2-(allylamino)-4-aminothiazol-5-yl)(phenyl)methanone (1) was selected for thorough structure−activity relationship (SAR) analysis using medicinal chemistry and protein crystallography, yielding compounds with high potency and selectivity against CDK2 and CDK5 over CDK9, CDK1, CDK4, and CDK6. Compound 51 inhibited the proliferation/survival of five cancer cell lines with IC 50 values ≤0.5 μM, suppressed CDK-specific phosphorylation of the Rb protein, and induced activation of caspase-3. The comprehensiveness of this experimental structure−activity data, including 35 cocrystal structures of CDK2 with analogues of the parent compound, provides valuable guidance for the refinement of algorithms used in molecular docking simulations and structure-based drug design.
■ RESULTS AND DISCUSSION
HTS Hit Identification and Characterization. We discovered compound 1 (2-(allylamino)-4-aminothiazol-5-yl-(phenyl)methanone) by high-throughput screening (HTS) as an inhibitor of the human CDK2-cyclin A2 complex with an IC 50 value of 15 μM. The cocrystal structure with CDK2 at 1.85 Å resolution ( Figure 1 , Table S1 in Supporting Information) confirmed that 1 belongs to the type I class of kinase inhibitors, binding to the ATP site through hydrogen bonding interactions between the thiazolamine moiety and the hinge region (Glu81−Leu83). A water molecule bridges the carbonyl oxygen of 1 and the backbone amide nitrogen of Asp145, while the phenyl and allyl moieties establish van der Waals carbon− carbon interactions (3.2 Å < d < 3.8 Å) with neighboring residues. Compounds with aminothiazole hinge-binding scaffolds have been previously described as inhibitors of checkpoint kinase I, 24 p38α/MAPK, 25 CDK2, 26 and CDK5. 27−29 However, the diaminothiazole CDK-inhibitors developed herein are unique with respect to structure, potency, and selectivity.
Structure−Activity Relationship (SAR) Studies. Analogues of 1 were designed such that the hinge-binding functionality of the aminothiazole core remained unchanged, while the flanking allyl (R1) and phenyl (R2) moieties were systematically modified ( Figure 2 , Table 1 ). A total of 95 analogues were synthesized and evaluated using three different enzymatic assays based on their inhibitory activities (see Experimental Section). The pyruvate kinase/lactate dehydrogenase (PK−LDH) spectrophotometric assay was employed for HTS and initial SAR studies. As the CDK2−cyclin A concentration in the PK−LDH assay limits the determination of IC 50 values up to ∼0.1 μM, a more sensitive fluorescencebased assay was employed for inhibitors with submicromolar activities, which allowed accurate IC 50 determinations up to ∼0.02 μM ( Figure S1 of Supporting Information). Activities of the most potent compounds were determined using a highly sensitive P 33 -radiolabeled activity assay. 30 The pan-kinase inhibitor staurosporine (IC 50 < 1 nM against CDK2−cyclin A) served as a control. Crystal structures of 35 CDK2− inhibitor complexes were determined between 1.4 and 2.0 Å resolution (Table S1 of Supporting Information). Scheme 1 shows the general method for synthesis of the targeted compounds. An isothiocyanate is reacted with cyanamide in the presence of tert-butoxide in THF for 15 min to form the intermediate addition product, which is directly reacted with a bromoacetyl derivative to form the desired (2,4-diaminothiazol-5-yl)methanone derivative.
Modifications to R2 resulted in analogues 2−15 (Table 1a) , of which the meta-pyridine analogue (3) was 5-fold more active (IC 50 = 3.1 μM) than the parent compound. This is likely due to the weak hydrogen bonding potential of the pyridine nitrogen with the ε-amino group of Lys33 (Figure 3a) , which establishes a salt bridge with Glu51 of the PSTAIRE helix in the activated CDK2−cyclin A2 complex. 31 Remarkably, substitution with ortho-or para-pyridine (6, 10) resulted in loss of activity, and cocrystal structures suggest that Lys33 is no longer attracted to the pyridine ring (Figure 3b, 3c) . Moreover, binding of 10 induced a large conformational change in the Ploop (residues Gly11−Val18), allowing a water molecule to enter and to interact with the ring nitrogen, while 6 adopts an unfavorable conformation upon binding to the active site. Modifications to R1 yielded analogues 16−25 (Table 1b) , of which the phenyl (16) and cyclohexyl (17) substituents yielded more than a 15-fold improvement in activity over the parent compound. Combination of a meta-pyridine ring at R2 (as in compound 3) with a phenyl group at R1 (as in compound 16) further improved inhibitory activity (30, IC 50 = 0.65 μM). However, with a phenyl group at R1, substituents at R2 other than meta-pyridine were not tolerated as well or were detrimental to compound activity (Table 1c ). Bulky R1 functional groups extend into a region commonly referred to as the front specificity pocket, consisting of residues Gln85, Asp86, and Lys89. To interrogate this pocket, we next synthesized a series of analogues with meta-pyridine at R2 and diverse substituents at R1 (Table 1d ). Introduction of a sulfonamide moiety at the para position of the phenyl ring yielded significant improvement over the parent compound (42, IC 50 = 0.02 μM). Using the fluorescence-based assay, the CDK2−cyclin A concentration of 9 nM became limiting for highly potent inhibitors such as 42. Even the pan-kinase inhibitor staurosporine, which is a known subnanomolar inhibitor of CDK2−cyclin A, displayed an IC 50 value of 20 nM in the fluorescence-based assay. Therefore, a highly sensitive P 33 -radiolabel assay was employed, in which 42 inhibited the CDK2−cyclin A complex with an IC 50 value of 0.9 nM ( Figure S2 of Supporting Information), rendering this compound among the most potent CDK2 inhibitors reported to date. 17 This 15000-fold increase in activity over the parent compound is primarily attributed to an elaborate hydrogen bonding network between the sulfonamide group and residues His84, Gln85, Asp86, and Lys89 (Figure 4a ). Of the other R1 substituents tested, the para-benzamide also conferred a considerable increase in activity (43, IC 50 = 0.22 μM). Introduction of a sulfonamide group in the meta position resulted in a loss of activity (49, IC 50 = 7.8 μM), and modifications to 49 did not restore inhibitory activity (78−83, Table S2 of Supporting Information).
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Several analogues of 42 were prepared with modifications to R2, of which compounds 51−55 were the most potent inhibitors, with IC 50 values between 0.02 and 0.07 μM (Table 1e ). Using the P 33 -radiolabeled assay, 51 inhibited CDK2−cyclin A2 with an IC 50 value of 1.5 nM ( Figure S2 of Supporting Information). Intriguingly, the ortho-nitro group of 51 is nested in a hydrophobic pocket composed of residues Val18, Ala31, Lys33, and gatekeeper Phe80 (Figure 4b ). The unusual proximity and orientation of the nitro group toward the Phe80 side chain indicate attractive interactions through van der Waals forces or the establishment of "nonclassical" hydrogen bonds between the phenyl ring and the nitro group, a phenomenon previously described for the interaction of nitro-substituted inhibitors of aldolase reductase with an active site tyrosine ring. 32 This notion is supported by the observation that other substitutions in the ortho position, such as methyl (62) or methylester (68), were detrimental to inhibitory activity. Although 52−55 displayed similar activities, the binding interactions of the respective R2 substituents are markedly different ( Figure 5 ). The meta-substituents of 52 (fluorine), 54 (nitro), and 56 (methoxy) share the same binding pocket, composed of residues Gly13, Val18, Lys33, and Asp145, whereas the meta-amino group of 55 causes the ring to rotate by ∼180°to form hydrogen bonds with Gln131 and Asn132. Other meta-substituents, such as trifluoromethyl (58), hydroxy (59), or chlorine (65), significantly decreased inhibitory activity. The para-sulfonamide moiety of 53 establishes hydrogen bonding interactions with Asn 132 and Asp145, but other para substituents, such as nitro (63), amino (64), methoxy (65), or bulky functional groups, resulted in loss of activity. Combined, these findings indicate that anchoring the inhibitor through a sulfonamide moiety in R1 allows diverse R2 substituents to efficiently interact with residues around Asp145 and the P-loop. Notably, introduction of aniline substituents in R1 to mimic the triazole carbothioamide structure of the highly potent pan-kinase inhibitor CDK1/2 inhibitor III resulted in complete loss of activity (Table S6 of Supporting Information).
Kinase Profiling. To assess kinase selectivity, a representative set of inhibitors was initially profiled against a panel of 48 different kinases ( Figure S3 of Supporting Information). GSK3β, a well-known cross-reactive target of CDK2 inhibitors, 33, 34 was the only other kinase significantly affected by these compounds. Next, compound 51 was thoroughly characterized using the P 33 -radiolabeled assay against a panel of different CDK−cyclin complexes together with GSK3β (Table 2, Figure S4 of Supporting Information). The highest inhibitory activity was seen against CDK2 and CDK5 (IC 50 values between 1.1 and 1.8 nM), followed by CDK1, CDK4, and CDK6 (IC 50 values between 4.0 and 7.6 nM), CDK9 and CDK3 (IC 50 values of 13 and 38 nM), and CDK7 (IC 50 > 1 Table  S7 of Supporting Information). The data confirmed that 51 is highly selective against CDKs within the human kinome (Figure 6b ). Compound 51 displayed highest inhibitory activity against CDK5 and CDK2 (95−96%), followed by CDK9 and CDK1 (90−93%) and CDK4 and CDK6 (87 and 85%). GSK3α and ERK7 were inhibited to 73−75%, followed by TAO1, GSK3β, and CLK2 (60−66%). The vast majority of kinases (282) Figure S6 of Supporting Information). In contrast, 42 was much less potent (IC 50 = 2.8 μM), suggesting that the R2 pyridine moiety negatively impacts cellular uptake of the inhibitor. This is supported by the observation that the pyridine-containing 45 was equally less effective (IC 50 = 3.1 μM) as compared to 51, whereas the fluorophenyl moiety of 52 conferred higher cellular activity (IC 50 = 0.85 μM). As expected from its poor in vitro activity against CDK2, compound 69 displayed the lowest ability to inhibit MDA-MB-468 cells (IC 50 = 5.5 μM). To assess the ability of the compounds to selectively inhibit the division of testis cells important for spermatogenesis, MTT assays were carried out using cell lines that represent important spermatogenic stages where cell division is critical for maintenance of spermatogenesis: spermatogonia (GC-1) 35, 36 and spermatocytes (GC-2). 36, 37 The results were compared to TM-4 cells, 38, 39 which represent Sertoli cells that normally stop dividing by the time spermatogenesis has commenced. Most compounds showed moderate to poor activity against these cell lines, with IC 50 values between 4 and 20 μM (Table 3) . Compounds 51, 52, and 57 showed higher activity against spermatocyte-derived cells (GC2) over spermatogonial-derived cells (GC1) cells and a Sertoli cell line (TM-4).

Next we determined the cellular activity of compounds 51, 52, 53, 55, and 69 against a panel of 14 different cancer cell lines using a resazurin/resorufin-based fluorescence assay ( Table 4 Compound 52 displayed a similar activity profile with IC 50 values between 0.45 and 6.8 μM for 13 cell lines but was significantly less active in those cell lines that were prominently inhibited by 51. The weak CDK2 inhibitor 69 was largely ineffective, and the potent CDK2 inhibitors 53 and 55 were also ineffective, presumably due to poor cell permeability. As expected, dinaciclib was extremely effective against most cell lines with IC 50 values between <0.005 and 0.01 μM. Notably, the BT-549 cell line was tolerant to all CDK2 inhibitors including dinaciclib but was sensitive to doxorubicin (IC 50 = 0.11 μM).
Mechanism of Action of Compound 51. To evaluate if the antiproliferative activity of 51 is caused by inhibition of cellular CDK2, we selected inhibition of Rb phosphorylation at the CDK-specific sites Ser807/811 and activation of caspase-3 at the onset of apoptosis as mechanism-based markers for CDK-specific inhibitors. 8, 22 The most sensitive cell line (A-673) and a moderately inhibited H929 cell line were treated for 24 h with compound 51 or dinaciclib and were evaluated by immunoblotting and caspase-3 activation (Figure 7 ). Compound 51 suppressed phosphorylation of the Rb protein above 0.25 μM in A-673 cells (Figure 7a ), which is in accord with the IC 50 value of 0.27 μM in cell viability assays. The activity of caspase-3 was increased by 196% with a half-maximal effective concentration (EC 50 ) of 0.4 μM. Dinaciclib completely suppressed phosphorylation of Rb Ser807/811 at 0.05 μM Scheme 1 Figure 3 . Influence of R2 pyridine substituents on binding interactions with CDK2. Crystal structures of CDK2 liganded with the pyridine analogues 3 (a), 6 (b), and 10 (c). meta-Pyridine (3) attracts the ε-amino group of Lys33, whereas para-pyridine (10) induces a large conformational change in the P-loop, allowing a water molecule to interact with the ring nitrogen. The ortho-pyridine (6) adopts a conformation unfavorable for interaction with CDK2. Figure 3d shows the differences in binding interactions upon superposition of the crystal structures. The enzymes are shown in gray with the hinge region (residues 81−83) colored in orange, the gatekeeper Phe80 residue in red, and Asp145 of the DFG motif in cyan. The hydrogen bonding interactions between the inhibitors (yellow) and enzyme residues are shown as black dotted lines. The key water molecules are shown as cyan spheres, with the 2F o − F c electron density map shown as a blue mesh around the inhibitor, and a green mesh around the water both contoured at 1σ. PDB entries 3QTQ, 3S0O, and 3R8Z. . Addition of a para-phenyl sulfonamide moiety at R1 substantially increased the inhibitory activity through establishment of a hydrogen bonding network with residues of the front specificity pocket (top exploded view). Addition of an ortho-nitrophenyl group at R1 of 51 retained the high in vitro activity and substantially increased cellular activity. The exploded view (bottom) shows the unusual proximity of the nitro group to neighboring hydrophobic residues. The 2F o − F c electron density is displayed as blue mesh, contoured at 1σ around the compound. Hydrogen bonding and potential π-bonding interactions are shown as black and orange dotted lines, respectively. Table 1e . The respective 2F o − F c density maps, contoured at 1σ, are shown as blue mesh. Black, green, and orange dotted lines indicate potential hydrogen bonding, hydrophobic, and π-interactions, respectively. PDB entries 3QTZ, 3QTU, 3QTX, and 3RPV. (Table 4) seems to corroborate the notion that suppression of Rb-phosphorylation is the primary mode of action of 51. However, the MDA-MB-468 cell line is also Rbdeficient but sensitive to 51 (Table 3) , indicating the involvement of other essential CDK substrates or possible off-target interactions. A more thorough cell-based study is planned to further address the mechanism of action of this inhibitor series using multiple marker analysis. 8 Although compound 51 and dinaciclib share similar CDK inhibitory and selectivity profiles in enzymatic activity assays, dinaciclib is an extremely potent antiproliferative compound in cancer cell lines. 8, 22 The modest activity of our inhibitors in cell-based assays suggests poor cell permeability, and a new series of compounds is planned with suitable solubilizing groups in solvent exposed regions to facilitate cellular uptake. Combined, these results demonstrate the potential of these inhibitors for further development into CDK-specific chemical probes and therapeutics. DMEM, penicillin, and streptomycin were purchased from Invitrogen (Carlsbad, CA). Fetal bovine serum was obtained from Atlanta Biologicals (Atlanta, GA), and MTT reagent was purchased from Sigma-Aldrich. Chemical Synthesis. Commercially available chemicals were used as purchased without further purification. THF was dried over an activated alumina column before use. 1 H NMR spectra were obtained on a 400 MHz spectrometer, and chemical shifts (ppm) were referenced to the residual solvent peak. 13 C NMR spectra were recorded at 100 MHz, and chemical shifts (ppm) were referenced to the appropriate residual solvent peak. High-resolution mass spectra (HRMS) were recorded with electrospray ionization. NMR spectra are shown in the Supporting Information. Compounds were purified by HPLC to >95% purity as reflected by their ability to readily cocrystallize with CDK2. The synthesis of 42 is given as a representative procedure that was used for the synthesis of the targeted library (* denotes that cocrystal structures with CDK2 were obtained).
*4-(4-Amino-5-nicotinoylthiazol-2-ylamino)benzenesulfonamide (42) . At 20°C, a mixture of 4-isothiocyanatobenzenesulfonamide (2.14 g, 10 mmol) and cyanamide (0.42 g, 10 mmol) in tetrahydrofuran (35 mL) was treated with potassium tert-butoxide (2.46 g, 22 mmol) for 15 min. 3-(2-Bromoacetyl)pyridinium bromide (2.66 g, 9.5 mmol) was added, and the suspension was stirred for 6 h. The solvent was removed, and the semisolid residue was triturated with water to give the crude product, which was filtered and dried in a vacuum oven at 50°C for 2 h. The dried crude product was recrystallized from EtOAc:DMF (8:2), which provided 2.2 g (60%) of 4-(4-amino-5-nicotinoylthiazol-2-ylamino)benzenesulfonamide as a yellow solid: mp (EtOAc/DMF) 218−220°C. 1 , DMSO-d 6 ) δ 178.3, 177.9, 167.1, 149.4, 145.0,  144.5, 143.9, 139.9, 138.3, 129.8, 129.3, 125.3, 121.8, 120.3, 115.9 . HRMS calcd for C 15 Enzyme Assays. The synthetic peptide PKTPKKAKKL 42 served as a substrate for the activated CDK2−cyclin A2 complex, and the formation of ADP from ATP was coupled to the oxidation of NADH using pyruvate kinase (PK) and lactate dehydrogenase (LDH), monitored at 340 nm. 43, 44 Assays for the HTS campaign (Z-factor = 0.74) and dose−response measurements for SAR were carried out in 384-well plates at room temperature in 50 mM Tris-HCl buffer (pH 7.5) containing 10 mM MgCl 2 , 0.24 mM NADH, 5 mM DTT, 6 U mL −1 LDH, 10 U mL −1 PK, 1 mM phosphoenolpyruvate, 5% (v/v) DMSO, and 0.15 μM (0.01 mg mL −1 ) activated CDK−cyclin A2 complex. Inhibitor was added to the mixture, and the reaction was initiated by the addition of 0.2 mM ATP and 0.125 mM peptide substrate. The more sensitive ADP Quest fluorescence assay (DiscoveRx, Fremont, CA) 45 was employed for compounds with IC 50 values below 1.0 μM. In this assay, the formation of ADP is coupled to the generation of a fluorescent resorufin dye (excitation and emission wavelengths of 540 and 590 nm, respectively). Reactions were carried out at room temperature in 15 mM HEPES buffer (pH 7.4) containing 20 mM NaCl, 1 mM EGTA, 0.02% Tween 20, 10 mM MgCl 2 , 5% (v/v) DMSO, and 8.8 nM (0.56 μg mL −1 ) activated CDK2−cyclin A2. Inhibitor was added to the mixture, and the reaction was initiated by the addition of 150 μM ATP and 100 μM peptide substrate. All kinetic assays were performed in 384-well plates using a Wallac Envision 2102 plate reader (Perkin-Elmer). IC 50 values were obtained by fitting data to eq 1, where A is the fraction of activity remaining, [I] is the concentration of inhibitor, and n is the Hill slope coefficient.
The most potent compounds, 42 and 51, were further analyzed by Reaction Biology Corporation (Malvern, PA) using a highly sensitive P 33 -radiolabeled assay against CDK2−cyclin A2. Kinase Profiling. Selected compounds were tested against a panel of 48 kinases provided by Caliper Life Sciences (Hopkinton, MA), which is representative of the entire human kinome. This kinase panel, available as ProfilerPro Kits 1 and 2, was tested using a Caliper LC3000 instrument in an electrophoretic mobility-shift assay at the High Throughput Screening Laboratory in the Institute for Therapeutics Discovery and Development at the University of Minnesota, College of Pharmacy. Compounds were added to the plates and preincubated with enzyme for 15 min, followed by addition of peptide substrates and ATP for a 90 min reaction period at 28°C. Inhibitory activity was determined by measuring the conversion of nonphosphorylated peptide substrate to phosphorylated product, expressed relative to plate controls. The Spotfire visualization program (Tibco Software, Palo Alto, CA) was used to generate a gradient heat map of the inhibitory activities ( Figure S3 of Supporting Information).
The profiling of compound 51 against a panel of 339 kinases and the dose−response kinetics against different CDK−cyclin complexes were performed by Reaction Biology Corp. using a P 33 -radiolabeled assay. Residual enzymatic activity (in % of DMSO controls) was determined in duplicate at a compound concentration of 0.1 μM for the profiling and between 0.05 nM and 1000 nM for the dose−response analysis; the ATP concentration was 10 μM and staurosporine served as a positive control.
X-ray Crystallography. Crystallization was performed at 19°C using the hanging drop vapor diffusion method. Crystals of CDK2− inhibitor complexes were grown from a solution of 10 mg mL −1 CDK2 in the presence of 0.5−3 mM compound with 0.1 M HEPES/NaOH (pH 7.5) and 10% (v/v) polyethylene glycol 3350. Crystals were harvested in cryoprotectant (50 mM HEPES pH 7.5, 50 mM phosphate (Na/K) pH 7.5, 15% (v/v) polyethylene glycol 3350, 23% (v/v) ethylene glycol, and 0.5 mM inhibitor) prior to data collection. X-ray diffraction data were recorded at −180°C in the Moffitt Cancer Center Chemical Biology Core using the rotation method on single crystals (Cu Kα radiation generated by Rigaku Micro-Max 007-HF, equipped with an HTC image plate and a Rigaku CCD Saturn 944 detector). The data set for compound 51 was recorded at the APS (Argonne National Laboratories) beamline 22-ID (SER-CAT) at a wavelength of 1.0 Å. Data were reduced with XDS 46 or HKL-2000. 47 
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48 was employed for phasing and refinement (minimization and simulated annealing), and model building was performed using O 49 or Coot. 50 Initial models for the inhibitors were generated using Chem3DPro (CambridgeSoft), and parameter and topology files were generated using xplo2d. 51 Figures were drawn with PyMol (Schrodinger, Inc.). Data and refinement statistics are shown in the Supporting Information (Table S1) , along with the F o − F c electron density maps from refinement cycles omitting the respective ligands ( Figure S5 of Supporting Information).
Cell Viability Assays. Cell lines were obtained from the American Type Culture Collection (Manassas, VA) and maintained in RPMI or DMEM with 10% fetal bovine serum, 37°C, and 5% CO 2 . All cell lines tested free of mycoplasma with MycoAlert tests (Lonza Rockland, Inc., Rockland, ME), and the cell line identities were confirmed using StemElite ID system (Promega Corp., Madison, WI).
For viability assays using MTT (3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide), cells were plated in 96-well plates in 100 μL of medium and were allowed to attach overnight. Cells were then incubated for 72 h with increasing concentrations of inhibitor. Media was aspirated and replaced with 100 μL of complete media containing 1 mg mL −1 MTT ((3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide) and incubated for 3 h at 37°C in 5% CO 2 humidified incubator. Media was then aspirated, and DMSO was added. Cells were incubated for 10 min at room temperature while shaking, and optical density was determined at 540 nm using a μQuant spectrophotometric plate reader (Bio-TEK, Winooski, VT). NCI-H929 and U266 cells were cultured in RPMI-1640 media (GIBCO, Life Technologies Carlsbad, CA), supplemented with 10% fetal bovine serum (GIBCO) including 0.05 mM 2-mercaptoethanol for NCI-H929 cells. Cells were plated in 96-well plate at a density of 10 × 10 3 cells/well. MTT assays with GC-1, GC-2, and TM-4 testis cells were carried out as above, with modifications in culture conditions as appropriate for these cell lines. 52−54 For viability assays using high-throughput CellTiter-Blue, 1200 cells were plated in each well of 384-well plates using a Precision XS liquid handling station (Bio-Tek Instruments, Inc., Winooski, VT) and allowed to incubate overnight at 37°C and 5% CO 2 . A liquid handling station was used to serially dilute all drugs (2:3) in media, and 6 μL of these dilutions were added to appropriate wells. Four replicate wells were used for each drug concentration, and an additional four control wells received a diluent control without drug. After a 72 h incubation period with drugs, 5 μL of CellTiter-Blue reagent (Promega Corp.) were added to each well. calculate the percent viability relative to the four replicate cell wells that did not receive drug. IC 50 values were determined using a sigmoidal equilibrium model regression using XLfit version 5.2 (ID Business Solutions Ltd.).
Assessment of Activated Caspase. Caspase 3/7 activation was measured using a plate-based Caspase-Glo 3/7 (Promega) luminescent assay. Cells were plated to white 384-well plates as described for cell viability assays. Cells were treated for 24 h with serial dilutions of each compound. For the detection of cleaved caspase-3, H929 cells were plated at a density of 4 × 10 5 cells/mL and treated with DMSO control, 1.5 μM compound 51, or 0.005 μM dinaciclib for 24 h. Cleaved caspase-3 levels were assessed using the mAb FITC Active caspase-3 apoptosis kit (BD Pharmingen). Samples were analyzed using a FACScan flow cytometer (BD Biosciences). The experiment was performed in triplicate.
Immunoblotting. A-673 cells were grown to ∼70% confluence, and compounds were added. After exposure to the compounds for 24 h, the cells were lysed in cell lysis buffer (Cell Signaling, Danvers, MA). The soluble protein concentration was determined using the Bio-Rad Protein Assay reagent, and 50 μg of total protein wad loaded on each lane of a 10% SDS-polyacrylamide gel. The proteins were then transferred to nitrocellulose membrane, washed with TBS/0.1% Tween 20, and incubated in 1× TBS−Tween20/2% BSA overnight at 4°C with primary antibodies. Antibody for phospho-Rb (Ser807/ 811, no. 9308) was obtained from Cell Signaling. β-Actin (clone AC-74) antibody was obtained from Sigma-Aldrich (St. Louis, MO; no. A2228). The membrane was then washed with TBS/0.1% Tween 20, incubated for 1 h at room temperature with goat antimouse 800 nm fluorescent and goat antirabbit 680 nm fluorescent labeled antibodies, and scanned on a Li-Cor (Lincoln, NE) Odyssey infrared scanner. H929 cells were plated at a density of 4 × 10 5 cells/mL. After treatment for 24 h, cells were washed with cold PBS and lysed in 100 μL of RIPA lysis buffer (Upstate, Lake Placid, NY). Then 10 μg of total protein was loaded on an 8% SDS-PAGE gel. Proteins were resolved by electrophoresis, transferred to a polyvinylidene fluoride (PVDF) membrane, and then blocked overnight in 5% nonfat milk in TBS-0.05% Tween-20. Protein levels were examined with antisera specific antibodies to pRb (Ser807/811) or GAPDH (Cell Signaling, Beverly, MA) and visualized with chemoluminescence (Pierce, Rockford, IL).
■ ASSOCIATED CONTENT * S Supporting Information X-ray crystallography data and refinement statistics, F o − F c electron density omit maps, additional SAR data along with dose−response graphs, kinase profiling results, and NMR spectra. This material is available free of charge via the Internet at http://pubs.acs.org.
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